Page last updated: 2024-12-05

fusaric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fusaric acid is a mycotoxin produced by the fungal pathogen Fusarium spp. It is a potent phytotoxin and exhibits antibacterial, antifungal, and cytotoxic activities. Fusaric acid is synthesized through a complex pathway involving multiple enzymes and intermediates. It is commonly found in cereal grains, fruits, and vegetables, posing a risk to human and animal health. Fusaric acid research focuses on understanding its biosynthesis, toxicity, and potential applications in agriculture and medicine. Studies explore its role in plant diseases, its effects on immune system, and its potential as a source of novel bioactive compounds. Due to its toxicity, fusaric acid is a subject of concern in food safety and animal feed.'

Fusaric Acid: A picolinic acid derivative isolated from various Fusarium species. It has been proposed for a variety of therapeutic applications but is primarily used as a research tool. Its mechanisms of action are poorly understood. It probably inhibits DOPAMINE BETA-HYDROXYLASE, the enzyme that converts dopamine to norepinephrine. It may also have other actions, including the inhibition of cell proliferation and DNA synthesis. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3442
CHEMBL ID24510
CHEBI ID5199
SCHEMBL ID178006
MeSH IDM0008907

Synonyms (97)

Synonym
jwj963070n ,
unii-jwj963070n
5-22-02-00384 (beilstein handbook reference)
MLS002153813
smr001233184
BRD-K87049188-001-03-6
EU-0100526
fusaric acid, from gibberella fujikuroi
LOPAC0_000526
einecs 208-643-0
fusarinic acid
hsdb 3487
nsc 19870
5-butylpyridine-3-carboxylic acid
brn 0125804
nsc-19870
wln: t6nj bvq e4
5-n-butylpyridine-2-carboxylic acid
2-pyridinecarboxylic acid, 5-butyl-
picolinic acid, 5-butyl-
nsc19870
5-butyl-2-pyridinecarboxylic acid
5-butylpicolinic acid
PRESTWICK_233
lopac-f-6513
NCGC00015441-03
NCGC00015441-02
cas-536-69-6
NCGC00015441-01
tnp00268 ,
PRESTWICK2_000442
BPBIO1_000534
5-butylpyridine-2-carboxylic acid
BSPBIO_000484
fusaric acid
536-69-6
NCGC00093919-02
SPBIO_002423
PRESTWICK0_000442
PRESTWICK1_000442
PRESTWICK3_000442
OPREA1_115508
NCGC00093919-01
NCGC00093919-03
F-9000
inchi=1/c10h13no2/c1-2-3-4-8-5-6-9(10(12)13)11-7-8/h5-7h,2-4h2,1h3,(h,12,13
NCGC00015441-04
F 6513
NCGC00015441-08
chebi:5199 ,
CHEMBL24510 ,
F0227
HMS1569I06
5-butyl-pyridine-2-carboxylic acid
bdbm50000439
5-butyl-pyridine-2-carboxylic acid (fusaric acid)
A19903
HMS3261J13
HMS2096I06
dtxsid5023085 ,
tox21_110149
dtxcid703085
CCG-204616
HMS2230M05
NCGC00015441-06
NCGC00015441-07
NCGC00015441-05
FT-0626585
LP00526
AKOS015891748
HMS3369P03
fusaric acid [mi]
fusaric acid [hsdb]
fusaric acid [mart.]
fusaric acid [jan]
SCHEMBL178006
NCGC00261211-01
tox21_500526
5-n-butylpicolinic acid
5-n-butyl picolinic acid
NCGC00015441-10
mfcd00006298
5-n-butyl-2-picolinic acid
SR-01000075634-1
sr-01000075634
fusaric acid, for hplc derivatization, >=99.0% (hplc)
AS-57621
fusarinic acid, 2.5-butylpicolinic acid, piconlinic acid
Q905703
cqv ,
SDCCGSBI-0050509.P002
NCGC00015441-15
STL564384
4-(acetylamino)-6-nitro-1,3-benzenedicarboxylicacid
T72585
CS-0099145
HY-128483

Research Excerpts

Overview

Fusaric acid (FA) is a secondary fungal metabolite, which is widespread on corn and corn-based feed and food; FA has non-specific toxicity. FA is a well-known mycotoxin that plays an important role in plant pathology. FA has been associated with plant disease development, although its role is still not well understood.

ExcerptReferenceRelevance
"Fusaric acid is a secondary metabolite produced by various Fusarium fungi, present with relatively high incidence in Fusarium-contaminated foods. "( A target fishing study to spot possible biological targets of fusaric acid: Inhibition of protein kinase-A and insights on the underpinning mechanisms.
Aichinger, G; Dall'Asta, C; Del Favero, G; Dellafiora, L; Hohenbichler, J; Marko, D, 2022
)
2.4
"Fusaric acid (FA) is a secondary fungal metabolite, which is widespread on corn and corn-based feed and food; FA has non-specific toxicity. "( Biosensor approach for electrochemical quantitative assessment and qualitative characterization of the effect of fusaric acid on a culture-receptor.
Antipova, TV; Emelyanova, EV, 2022
)
2.37
"Fusaric acid is a derivative of picolinic acid produced by some Fusarium species. "( Fusaric acid inhibits cell proliferation and downregulates expressions of toll-like receptors pathway genes in Ishikawa endometrial cancer cells.
Gulbay, G; Mutlu, D; Secme, M, 2023
)
3.8
"Fusaric acid (FSA) is a phytotoxin produced by several Fusarium species and has been associated with plant disease development, although its role is still not well understood. "( Fusaric acid instigates the invasion of banana by Fusarium oxysporum f. sp. cubense TR4.
Bi, F; Deng, G; Dong, T; Dou, T; Gao, H; Hu, C; Li, C; Li, J; Liu, N; Liu, S; Ma, LJ; Mostert, D; Sheng, O; Viljoen, A; Yang, Q; Yi, G; Zhang, Y; Zuo, C, 2020
)
3.44
"Fusaric acid (FA) is a ubiquitous yet neglected mycotoxin. "( Molecular docking and mechanisms of fusaric acid induced mitochondrial sirtuin aberrations in glycolytically and oxidatively poised human hepatocellular carcinoma (HepG2) cells.
Abdul, NS; Anand, K; Chuturgoon, AA; Nagiah, S, 2020
)
2.28
"Fusaric acid (FA) is a food-borne mycotoxin that mediates toxicity with limited information on its epigenetic properties. "( Fusaric acid decreases p53 expression by altering promoter methylation and m6A RNA methylation in human hepatocellular carcinoma (HepG2) cells.
Chuturgoon, AA; Ghazi, T; Nagiah, S, 2021
)
3.51
"Fusaric acid (FA) is a well-known mycotoxin that plays an important role in plant pathology. "( Biosynthesis of Mycotoxin Fusaric Acid and Application of a PLP-Dependent Enzyme for Chemoenzymatic Synthesis of Substituted l-Pipecolic Acids.
Chen, M; Hai, Y; Huang, A; Tang, Y, 2020
)
2.3
"Fusaric acid (FA) is a novel compound derived from a class of nicotinic acid derivatives, exhibiting activity against cancers. "( Fusaric acid (FA) protects heart failure induced by isoproterenol (ISP) in mice through fibrosis prevention via TGF-β1/SMADs and PI3K/AKT signaling pathways.
Li, X; Wang, HF; Zhang, ZL, 2017
)
3.34
"Fusaric acid (FA) is a fungal metabolite produced by several Fusarium species responsible for wilts and root rot diseases of a great variety of plants. "( A novel Burkholderia ambifaria strain able to degrade the mycotoxin fusaric acid and to inhibit Fusarium spp. growth.
Gomez, FM; Gutierrez-Boem, FH; Montecchia, MS; Roberts, IN; Ruiz, JA; Simonetti, E, 2018
)
2.16
"Fusaric acid (FA) is a neglected fusarium mycotoxin despite its ubiquitous presence. "( Fusaric acid induces NRF2 as a cytoprotective response to prevent NLRP3 activation in the liver derived HepG2 cell line.
Chuturgoon, AA; Nagiah, S; Sheik Abdul, N, 2019
)
3.4
"Fusaric acid (FA) is a nonhost-selective toxin mainly produced by Fusarium oxysporum, the causal agent of plant wilt diseases. "( Fusaric acid induction of programmed cell death modulated through nitric oxide signalling in tobacco suspension cells.
Gao, Z; Jiao, J; Liang, Y; Zhou, B; Zhu, X, 2013
)
3.28
"Fusaric acid (FA) is a novel compound from a novel class of nicotinic acid derivatives that have activity against head and neck squamous cell carcinoma (HNSCC)."( Determination of oral bioavailability of fusaric acid in male Sprague-Dawley rats.
Hendrickson, HP; Hubbard, M; Stack, BC; Willis, R; Ye, J, 2014
)
1.39
"Fusaric acid is a polyketide-derived SM produced by multiple species of the fungal genus Fusarium."( Identification of a 12-gene Fusaric Acid Biosynthetic Gene Cluster in Fusarium Species Through Comparative and Functional Genomics.
Brown, DW; Busman, M; Kim, LH; Kim, YH; Lee, S; Lee, SH; Lee, T; Proctor, RH; Ryu, JG; Seo, Y; Yun, SH, 2015
)
1.43
"Fusaric acid (FA) is a key component in virulence and symptom development in cotton during infection by Fusarium oxysporum. "( FUBT, a putative MFS transporter, promotes secretion of fusaric acid in the cotton pathogen Fusarium oxysporum f. sp. vasinfectum.
Bell, AA; Crutcher, FK; Liu, J; Nichols, RL; Puckhaber, LS; Stipanovic, RD, 2015
)
2.11
"Fusaric acid (FSA) is a mycotoxin produced by several fusaria, including the rice pathogen Fusarium fujikuroi. "( Two separate key enzymes and two pathway-specific transcription factors are involved in fusaric acid biosynthesis in Fusarium fujikuroi.
Arndt, B; Burkhardt, I; Dickschat, JS; Humpf, HU; Janevska, S; Niehaus, EM; Sieber, CM; Studt, L; Tudzynski, B, 2016
)
2.1
"Fusaric acid (FA) is a toxin produced by Fusarium species. "( Early physiological responses of Arabidopsis thaliana cells to fusaric acid: toxic and signalling effects.
Amiar, Z; Bouizgarne, B; Bouteau, F; Brault, M; Briand, J; El Hadrami, I; El-Maarouf-Bouteau, H; Frankart, C; Madiona, K; Monestiez, M; Ouhdouch, Y; Pennarun, AM; Reboutier, D; Rona, JP; Trouverie, J, 2006
)
2.02
"Fusaric acid was shown to be a mild toxin to the eggs and when a relatively nontoxic concentration of it was combined with graded doses of fumonisin B1, a synergistic toxic response was obtained."( Toxic interaction of fumonisin B1 and fusaric acid measured by injection into fertile chicken egg.
Bacon, CW; Norred, WP; Porter, JK, 1995
)
1.28
"Fusaric acid is a mycotoxin with low to moderate toxicity, which is of concern since it might be synergistic with other cooccurring mycotoxins. "( Production of fusaric acid by Fusarium species.
Bacon, CW; Leslie, JF; Norred, WP; Porter, JK, 1996
)
2.1

Effects

Fusaric acid calcium salt has a history of usage as a hypotensive agent in humans with no observed toxicity.

ExcerptReferenceRelevance
"Fusaric acid calcium salt has a history of usage as a hypotensive agent in humans with no observed toxicity."( In vitro acanthamoebicidal activity of fusaric acid and dehydrofusaric acid from an endophytic fungus Fusarium sp. Tlau3.
Boonman, N; Boonmee, A; Dharmkrong-At Chusattayanond, A; Kittakoop, P; Prachya, S; Sriubolmas, N; Warit, S; Wiyakrutta, S, 2012
)
1.37
"Fusaric acid calcium salt has a history of usage as a hypotensive agent in humans with no observed toxicity."( In vitro acanthamoebicidal activity of fusaric acid and dehydrofusaric acid from an endophytic fungus Fusarium sp. Tlau3.
Boonman, N; Boonmee, A; Dharmkrong-At Chusattayanond, A; Kittakoop, P; Prachya, S; Sriubolmas, N; Warit, S; Wiyakrutta, S, 2012
)
1.37
"Fusaric acid has been isolated and identified from a strain of F."( HPLC analysis of fusaric acid, 9,10-dehydrofusaric acid and their methyl esters, toxic metabolites from weed pathogenic Fusarium species.
Amalfitano, C; Andolfi, A; Evidente, A; Pengue, R; Vurro, M; Zonno, MC,
)
1.19

Actions

ExcerptReferenceRelevance
"Fusaric acid was found to cause a selective dose- and time-dependent inhibition of DBH activity in the medial basal hypothalamus without altering tyrosine hydroxylase activity."( Inhibition of LH and prolactin release in the cycling rat following inhibition of dopamine-beta-hydroxylase.
Carr, LA; Voogt, JL, 1981
)
0.98

Treatment

Pretreatment with fusaric acid or diethyldithiocarbamate (inhibitors of dopamine-beta-hydroxylase) exerted no influence on the actions of alpha-MD on alpha 2-receptor sites. NSD-1055 (an inhibitor of dopa decarboxyl enzyme) inhibited the effects ofalpha-MD.

ExcerptReferenceRelevance
"Fusaric acid-treated bilaterally adrenalectomized rats did not exhibit any increase in plasma, heart and kidney E concentrations."( In vivo release of adrenal catecholamines in rats by fusaric acid.
Buu, NT; Kuchel, O; Racz, K, 1985
)
1.24
"Pretreatment with fusaric acid or diethyldithiocarbamate (inhibitors of dopamine-beta-hydroxylase) exerted no influence on the actions of alpha-MD on alpha 2-receptor sites, whereas NSD-1055 (an inhibitor of dopa decarboxylase) inhibited the effects of alpha-MD."( Effect of alpha-methyldopa on alpha-noradrenergic receptor binding sites in the mouse brain.
Oide, M, 1984
)
0.59
"Pretreatment with fusaric acid, an inhibitor of dopamine-beta-hydroxylase, also antagonizes the mydriatic effect of L-dopa."( The effect of L-dopa on pupillary diameter in mice.
Keren, O; Korczyn, AD, 1982
)
0.59

Toxicity

ExcerptReferenceRelevance
" Toxic synergism was obtained by simultaneous administration of FA and fumonisin B1 to chicks in ovo."( Fusaric acid and modification of the subchronic toxicity to rats of fumonisins in F. moniliforme culture material.
Bacon, CW; Meredith, FI; Norred, WP; Porter, JK; Voss, KA, 1999
)
1.75

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of FA was sufficient (58 %) to suggest that FA may be viable as an orally administered medication."( Determination of oral bioavailability of fusaric acid in male Sprague-Dawley rats.
Hendrickson, HP; Hubbard, M; Stack, BC; Willis, R; Ye, J, 2014
)
0.67
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Fusaric acid antagonized acetylcholine and serotonin most effectively among these agonists. FusarIC acid produced a shift to the right and down in the dose-response curves to all tested agonists, including 15-HPAA.

ExcerptRelevanceReference
"In Experiment 1, the dose-response effects of three dopamine-beta-hydroxylase (DBH) inhibitors (diethyldithiocarbamate, FLA-63 and U-14, 624) on the endogenous levels of norepinephrine and dopamine in pons-medulla of rat brain were determined."( Possible role of dopamine-beta-hydroxylase in the regulation of norepinephrine biosynthesis in rat brain.
Belluzzi, JD; Stein, L; Wise, CD, 1977
)
0.26
" Fusaric acid produced a shift to the right and down in the dose-response curves to all tested agonists, and antagonized acetylcholine and serotonin most effectively among these agonists."( Relaxation of isolated rabbit arteries by fusaric (5-butylpicolinic) acid.
Asano, M; Hidaka, H, 1976
)
1.17
" In the presence of 1 X 10(-3) M fusaric acid, the dose-response curves of cerebral arteries for 15-HPAA were antagonized in a noncompetitive manner."( Contractile responses of mammalian cerebral arteries to 15-hydroperoxyarachidonic acid vary in the presence of fusaric acid and verapamil.
Asano, M; Hidaka, H; Matsuda, T; Suzuki, Y, 1984
)
0.76
" Further nude mice studies are needed to optimize dosing and administration regimens for FA in anticipation of clinical trials."( Fusaric acid: a novel agent and mechanism to treat HNSCC.
Hansen, JP; Hollenbeak, CS; Jaglowski, J; Ruda, JM; Shvidler, J; Stack, BC, 2004
)
1.77
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
aromatic carboxylic acidAny carboxylic acid in which the carboxy group is directly bonded to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (56)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency23.78790.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency10.00000.044717.8581100.0000AID485294
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency11.55970.140911.194039.8107AID2451
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency19.54980.177814.390939.8107AID2147
endonuclease IVEscherichia coliPotency10.00000.707912.432431.6228AID1708
15-lipoxygenase, partialHomo sapiens (human)Potency11.07920.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency37.55430.141337.9142100.0000AID1490
NFKB1 protein, partialHomo sapiens (human)Potency3.16230.02827.055915.8489AID895; AID928
TDP1 proteinHomo sapiens (human)Potency33.49830.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency7.94330.180013.557439.8107AID1460
ThrombopoietinHomo sapiens (human)Potency1.99530.02517.304831.6228AID917; AID918
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency2.02470.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency9.18040.00137.762544.6684AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency25.11890.001318.074339.8107AID926; AID938
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency2.68370.01237.983543.2770AID1645841
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency22.38720.28189.721235.4813AID2326
estrogen nuclear receptor alphaHomo sapiens (human)Potency5.35380.000229.305416,493.5996AID743075
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency3.98110.707936.904389.1251AID504333
IDH1Homo sapiens (human)Potency18.35640.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency2.37240.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00320.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency60.119823.934123.934123.9341AID1967
runt-related transcription factor 1 isoform AML1bHomo sapiens (human)Potency20.89550.02007.985839.8107AID504370; AID504374
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency5.62340.01789.637444.6684AID588834
core-binding factor subunit beta isoform 2Homo sapiens (human)Potency20.89550.02007.985839.8107AID504370; AID504374
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency12.31940.00798.23321,122.0200AID2546; AID2551
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency8.91250.075215.225339.8107AID485360
gemininHomo sapiens (human)Potency18.15830.004611.374133.4983AID624296; AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency25.11890.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.14130.00106.000935.4813AID943
lamin isoform A-delta10Homo sapiens (human)Potency7.07950.891312.067628.1838AID1487
pyruvate kinase PKM isoform bHomo sapiens (human)Potency0.25122.511912.262825.1189AID954; AID958
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency19.95260.316212.765731.6228AID881
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency19.95260.00638.235039.8107AID881
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency28.18380.060110.745337.9330AID492961
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dopamine beta-hydroxylase Bos taurus (cattle)IC50 (µMol)0.05000.05001.49432.6000AID1682095
Dopamine beta-hydroxylase Bos taurus (cattle)Ki0.14900.04100.13220.3440AID61993; AID62121
Dopamine beta-hydroxylaseRattus norvegicus (Norway rat)IC50 (µMol)0.70000.70001.65452.6000AID62148
Transmembrane prolyl 4-hydroxylaseHomo sapiens (human)IC50 (µMol)149.00005.18005.39335.5000AID160194
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (25)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
dopamine catabolic processDopamine beta-hydroxylase Bos taurus (cattle)
norepinephrine biosynthetic processDopamine beta-hydroxylase Bos taurus (cattle)
regulation of erythrocyte differentiationTransmembrane prolyl 4-hydroxylaseHomo sapiens (human)
peptidyl-proline hydroxylation to 4-hydroxy-L-prolineTransmembrane prolyl 4-hydroxylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
dopamine beta-monooxygenase activityDopamine beta-hydroxylase Bos taurus (cattle)
copper ion bindingDopamine beta-hydroxylase Bos taurus (cattle)
L-ascorbic acid bindingDopamine beta-hydroxylase Bos taurus (cattle)
iron ion bindingTransmembrane prolyl 4-hydroxylaseHomo sapiens (human)
calcium ion bindingTransmembrane prolyl 4-hydroxylaseHomo sapiens (human)
2-oxoglutarate-dependent dioxygenase activityTransmembrane prolyl 4-hydroxylaseHomo sapiens (human)
L-ascorbic acid bindingTransmembrane prolyl 4-hydroxylaseHomo sapiens (human)
hypoxia-inducible factor-proline dioxygenase activityTransmembrane prolyl 4-hydroxylaseHomo sapiens (human)
procollagen-proline 4-dioxygenase activityTransmembrane prolyl 4-hydroxylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular spaceDopamine beta-hydroxylase Bos taurus (cattle)
transport vesicle membraneDopamine beta-hydroxylase Bos taurus (cattle)
chromaffin granule lumenDopamine beta-hydroxylase Bos taurus (cattle)
secretory granule lumenDopamine beta-hydroxylase Bos taurus (cattle)
chromaffin granule membraneDopamine beta-hydroxylase Bos taurus (cattle)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneTransmembrane prolyl 4-hydroxylaseHomo sapiens (human)
endoplasmic reticulumTransmembrane prolyl 4-hydroxylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (100)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1144035Antihypertensive activity in unanesthetized renal hypertensive Mongrel dog model assessed as change in mean blood pressure at 60 mg/kg, po qd measured on day 11978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and antihypertensive activity of 5-thio-2-pyridinecarboxylic acid derivatives.
AID61993Binding affinity towards Dopamine beta hydroxylase using tyramine substrate at pH 4.5 in the absence of fumarate1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Substituted 1-benzylimidazole-2-thiols as potent and orally active inhibitors of dopamine beta-hydroxylase.
AID1144052Antihypertensive activity in normotensive squirrel monkey model assessed as decrease in systolic blood pressure at 100 mg/kg, po qd measured on day 2 by sphygmomanometry1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and antihypertensive activity of 5-thio-2-pyridinecarboxylic acid derivatives.
AID1144057Toxicity in normotensive squirrel monkey model assessed as change in heart rate at 100 mg/kg, po qd measured on day 21978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and antihypertensive activity of 5-thio-2-pyridinecarboxylic acid derivatives.
AID566707Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID59046Antihypertensive activity in unanesthetized renal hypertensive dogs measured as mean Blood Pressure at 60 mg per kg dose after peroral administration on day 31980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Synthesis and antihypertensive activity of 5-amino-2-pyridinecarboxylic acid derivatives.
AID1436365Growth inhibition of Escherichia coli at 3.13 ug/ml2017European journal of medicinal chemistry, Jan-27, Volume: 126Fusaric acid and analogues as Gram-negative bacterial quorum sensing inhibitors.
AID1144064Toxicity in normotensive squirrel monkey model assessed as emesis at 100 mg/kg, po qd measured on day 21978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and antihypertensive activity of 5-thio-2-pyridinecarboxylic acid derivatives.
AID184114Percent increase in DA/NE ratio was determined from assay of DA and NE in the mesenteric artery of spontaneously hypertensive rat after two doses for 50 mg/kg peroral administration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Inhibitors of dopamine beta-hydroxylase. 3. Some 1-(pyridylmethyl)imidazole-2-thiones.
AID58320Antihypertensive activity in unanesthetized renal hypertensive dogs measured as Heart Rate (HR) (beats/min) at 60 mg per kg dose after peroral administration on day 21980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Synthesis and antihypertensive activity of 5-amino-2-pyridinecarboxylic acid derivatives.
AID566700Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1144062Toxicity in unanesthetized renal hypertensive Mongrel dog model assessed as emesis at 60 mg/kg, po qd measured on day 1 to 41978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and antihypertensive activity of 5-thio-2-pyridinecarboxylic acid derivatives.
AID1144037Antihypertensive activity in unanesthetized renal hypertensive Mongrel dog model assessed as change in mean blood pressure at 60 mg/kg, po qd measured on day 31978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and antihypertensive activity of 5-thio-2-pyridinecarboxylic acid derivatives.
AID534106Antibacterial activity against Pasteurella multocida AL435 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID1144051Antihypertensive activity in normotensive squirrel monkey model assessed as decrease in systolic blood pressure at 30 mg/kg, po qd measured on day 1 by sphygmomanometry1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and antihypertensive activity of 5-thio-2-pyridinecarboxylic acid derivatives.
AID534111Antibacterial activity against Pasteurella multocida pm1980 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID1436364Inhibition of LuxR-dependent quorum sensing activity in Escherichia coli harboring reporter plasmid LuxI-GFP assessed as reduction in 3-oxo-C6-HSL-induced GFP expression at 3.1 ug/ml measured every 15 mins for 14 hrs by fluorescence assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Fusaric acid and analogues as Gram-negative bacterial quorum sensing inhibitors.
AID1682098In vivo inhibition of DBH in rat assessed as norepinephrine expression in rat brain at 100 mg/kg, ip administered as single dose measured after 3 hrs by spectrophotofluorometric analysis (Rvb = 0.42 ug/g)2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID62148Inhibition of Dopamine beta hydroxylase in spontaneously hypertensive rats; Value ranges from 0.4-1.11987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Inhibitors of dopamine beta-hydroxylase. 3. Some 1-(pyridylmethyl)imidazole-2-thiones.
AID58322Antihypertensive activity in unanesthetized renal hypertensive dogs measured as Heart Rate (HR) (beats/min) at 60 mg per kg dose after peroral administration on day11980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Synthesis and antihypertensive activity of 5-amino-2-pyridinecarboxylic acid derivatives.
AID534110Antibacterial activity against TolC deficient Pasteurella multocida pm1980 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID185480DBH inhibitory activity was measured as dopamine levels in mesenteric artery at dose of 50 mg/kg, po1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Substituted 1-benzylimidazole-2-thiols as potent and orally active inhibitors of dopamine beta-hydroxylase.
AID1144063Toxicity in normotensive squirrel monkey model assessed as emesis at 30 mg/kg, po qd measured on day 11978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and antihypertensive activity of 5-thio-2-pyridinecarboxylic acid derivatives.
AID534112Ratio of MIC for Pasteurella multocida AL435 to MIC for TolC deficient Pasteurella multocida pm19802008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID1436363Inhibition of yeast Pma1 at 100 uM preincubated for 30 mins by spectrophotometric method2017European journal of medicinal chemistry, Jan-27, Volume: 126Fusaric acid and analogues as Gram-negative bacterial quorum sensing inhibitors.
AID59045Antihypertensive activity in unanesthetized renal hypertensive dogs measured as mean Blood Pressure at 60 mg per kg dose after peroral administration on day 21980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Synthesis and antihypertensive activity of 5-amino-2-pyridinecarboxylic acid derivatives.
AID534109Ratio of MIC for Pasteurella multocida AL435 to MIC for TolC deficient Pasteurella multocida pm05272008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID1682097In vivo inhibition of DBH in human assessed as reduction in 3-methoxy-4-hydroxy-phenylglycol level in cerebrospinal fluid at 1.12g administered for 10 to 20 days2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID376859Phytotoxicity in tomato leaf assessed as chlorosis in the leaf at 10'-5 M by tomato cutting assay2000Journal of natural products, Aug, Volume: 63, Issue:8
Biological characterization of fusapyrone and deoxyfusapyrone, two bioactive secondary metabolites of Fusarium semitectum.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1144045Toxicity in unanesthetized renal hypertensive Mongrel dog model assessed as change in heart rate at 60 mg/kg, po qd measured on day 31978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and antihypertensive activity of 5-thio-2-pyridinecarboxylic acid derivatives.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1436368Growth inhibition of Escherichia coli at 6.2 to 100 ug/ml2017European journal of medicinal chemistry, Jan-27, Volume: 126Fusaric acid and analogues as Gram-negative bacterial quorum sensing inhibitors.
AID1144029Antihypertensive activity in spontaneous hypertensive rat model assessed as decrease in blood pressure at 100 mg/kg, po administered for 2 to 4 days measured on day 2 to day 41978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and antihypertensive activity of 5-thio-2-pyridinecarboxylic acid derivatives.
AID1682101Inhibition of bovine adrenal medulla DBH at 0.5 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID172002The compound was tested for antihypertensive effect in spontaneously hypertensive rat (SHR), expressed as fall in blood pressure (BP) at 100 mg/kg dose given orally1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Synthesis and antihypertensive activity of 5-amino-2-pyridinecarboxylic acid derivatives.
AID1144043Toxicity in unanesthetized renal hypertensive Mongrel dog model assessed as change in heart rate at 60 mg/kg, po qd measured on day 11978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and antihypertensive activity of 5-thio-2-pyridinecarboxylic acid derivatives.
AID1436358Inhibition of RhlR-dependent quorum sensing activity in Pseudomonas aeruginosa harboring reporter plasmid rhlA-gfp assessed as reduction in GFP expression up to 100 ug/ml measured every 15 mins for 14 hrs by fluorescence assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Fusaric acid and analogues as Gram-negative bacterial quorum sensing inhibitors.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1682095Inhibition of bovine adrenal medulla DBH incubated for 25 mins2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1436357Inhibition of LasR-dependent quorum sensing activity in Pseudomonas aeruginosa harboring reporter plasmid lasB-GFP assessed as reduction in GFP expression up to 100 ug/ml measured every 15 mins for 14 hrs by fluorescence assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Fusaric acid and analogues as Gram-negative bacterial quorum sensing inhibitors.
AID1682104Inhibition of bovine adrenal medulla DBH at 0.005 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID62121Compound was evaluated for the inhibition of Dopamine beta hydroxylase at pH 4.51986Journal of medicinal chemistry, Dec, Volume: 29, Issue:12
Multisubstrate inhibitors of dopamine beta-hydroxylase. 1. Some 1-phenyl and 1-phenyl-bridged derivatives of imidazole-2-thione.
AID1436356Inhibition of LuxR-dependent quorum sensing activity in Escherichia coli harboring reporter plasmid LuxI-GFP assessed as reduction in 3-oxo-C6-HSL-induced GFP expression measured every 15 mins for 14 hrs by fluorescence assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Fusaric acid and analogues as Gram-negative bacterial quorum sensing inhibitors.
AID1144036Antihypertensive activity in unanesthetized renal hypertensive Mongrel dog model assessed as change in mean blood pressure at 60 mg/kg, po qd measured on day 21978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and antihypertensive activity of 5-thio-2-pyridinecarboxylic acid derivatives.
AID160194Inhibition of prolyl 4-hydroxylase activity by an indirect assay1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Novel inhibitors of prolyl 4-hydroxylase. 2. 5-Amide substituted pyridine-2-carboxylic acids.
AID1144056Toxicity in normotensive squirrel monkey model assessed as change in heart rate at 30 mg/kg, po qd measured on day 11978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and antihypertensive activity of 5-thio-2-pyridinecarboxylic acid derivatives.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID534107Antibacterial activity against TolC deficient Pasteurella multocida pm0527 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID534108Antibacterial activity against Pasteurella multocida pm0527 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1682103Inhibition of bovine adrenal medulla DBH at 0.05 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID59047Antihypertensive activity in unanesthetized renal hypertensive dogs measured as mean Blood Pressure at 60 mg per kg dose after peroral administration on day11980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Synthesis and antihypertensive activity of 5-amino-2-pyridinecarboxylic acid derivatives.
AID1682099In vivo inhibition of DBH in rat assessed as norepinephrine expression in rat brain at 100 mg/kg, ip administered as single dose measured after 3 hrs by spectrophotofluorometric analysis (Rvb = 0.22 ug/g)2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID58321Antihypertensive activity in unanesthetized renal hypertensive dogs measured as Heart Rate (HR) (beats/min) at 60 mg per kg dose after peroral administration on day 31980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Synthesis and antihypertensive activity of 5-amino-2-pyridinecarboxylic acid derivatives.
AID1144044Toxicity in unanesthetized renal hypertensive Mongrel dog model assessed as change in heart rate at 60 mg/kg, po qd measured on day 21978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and antihypertensive activity of 5-thio-2-pyridinecarboxylic acid derivatives.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1682102Inhibition of bovine adrenal medulla DBH at 1 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID173884Antihypertensive activity was determined by decrease in blood pressure response in spontaneously hypertensive rat was determined after intraperitoneal administration at a dose of 50 mg/kg1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Inhibitors of dopamine beta-hydroxylase. 3. Some 1-(pyridylmethyl)imidazole-2-thiones.
AID231971Ratio of dopamine to that of NE levels in mesenteric artery measured at 50 mg/kg po1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Substituted 1-benzylimidazole-2-thiols as potent and orally active inhibitors of dopamine beta-hydroxylase.
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (311)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990124 (39.87)18.7374
1990's34 (10.93)18.2507
2000's34 (10.93)29.6817
2010's85 (27.33)24.3611
2020's34 (10.93)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.38 (24.57)
Research Supply Index5.82 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index47.86 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (3.40%)5.53%
Reviews9 (2.78%)6.00%
Case Studies4 (1.23%)4.05%
Observational0 (0.00%)0.25%
Other300 (92.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]